ACTRN12617001355369已完成2 期
A clinical trial looking at the tolerability and side effects of using imiquimod to treat anal HPV in men who have sex with men and are HIV positive
The Alfred0 个研究点目标入组 31 人开始时间: 2017年9月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- Male
入选标准
- •a)Men who have sex with men and are between 18 and 85 years of age
- •b)Known HIV positive
- •c)Tested positive for any high risk HPV type(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and/or 68) at day of recruitment
- •d)Sufficient English language proficiency to understand the requirements of the study and complete the questionnaire
- •e)Provision of written informed consent
排除标准
- •a)Men who tested negative for all high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) at day of recruitment
- •b)Men who are unable to attend the scheduled week 8 and week 16 visits
- •c)Men who have been diagnosed with anal cancer in the last 12 months
- •d)Men who have an organ transplant or an autoimmune disorder requiring any systemic treatment
- •e)Transgender individuals
研究者
相似试验
进行中（未招募）
不适用
An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergyGrass pollen induced rhinoconjunctivitisMedDRA version: 12.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisEUCTR2009-014522-41-ATALK-Abelló A/S100
进行中（未招募）
不适用
An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergyEUCTR2009-014522-41-DEALK-Abelló A/S100
进行中（未招募）
不适用
An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergyGrass pollen induced rhinoconjunctivitisMedDRA version: 12.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisEUCTR2009-014522-41-DKALK-Abelló A/S100
已完成
不适用
A clinical trial to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of LEO 153339 in healthy subjectsPsoriasisNL-OMON51974eo Pharma A/S134
进行中（未招募）
1 期
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Based Treatment with Focus on Mechanisms of Resistance to Endocrine Based Treatment (fulvestrant/aromatase inhibitors alone or in combination with a cdk4/6 inhibitor) in Patients With Advanced Breast CancerEstrogen receptor positive metastatic or locally advanced inoperable breast cancer.MedDRA version: 20.0Level: LLTClassification code 10006192Term: Breast cancer NOSSystem Organ Class: 100000004864EUCTR2016-000494-20-SESkåne University Hospital, Department of Oncology126